title: Chemoradiation for Locally Advanced Unresectable Pancreatic Cancer-What Now?
authors.affiliation: Knight Cancer Institute, Brenden-Colson Center for Pancreatic Care, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon.
authors.forename: Gina
authors.initials: G
authors.lastname: Vaccaro
authors.affiliation: Knight Cancer Institute, Brenden-Colson Center for Pancreatic Care, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon.
authors.forename: Charles D
authors.initials: CD
authors.lastname: Lopez
mesh_terms: D059248:Chemoradiotherapy / Q000009:adverse effects*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D019583:Dose Fractionation, Radiation; D004334:Drug Administration Schedule; D000069347:Erlotinib Hydrochloride / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009026:Mortality; D010190:Pancreatic Neoplasms / Q000401:mortality* / Q000628:therapy*; D016019:Survival Analysis; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D000069347:Erlotinib Hydrochloride; D000093542:Gemcitabine